Pluri Inc. (PLUR): Operating Cash Flow
-$19.59M
Year ended 2026-06-30
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2026-06-30 | -$19.59M | n/m | 2026-09-10, From 2025-07-01 |
| 2025-06-30 | -$18.21M | n/m | 2026-09-10, From 2024-07-01 |
| 2024-06-30 | -$18.02M | n/m | 2025-09-17, From 2023-07-01 |
| 2023-06-30 | -$22.86M | n/m | 2024-09-18, From 2022-07-01 |
| 2022-06-30 | -$36.50M | n/m | 2023-09-12, From 2021-07-01 |
| 2021-06-30 | -$30.91M | n/m | 2022-09-21, From 2020-07-01 |
| 2020-06-30 | -$26.37M | n/m | 2021-09-13, From 2019-07-01 |
| 2019-06-30 | -$29.45M | n/m | 2020-09-10, From 2018-07-01 |
| 2018-06-30 | -$21.38M | n/m | 2020-09-10, From 2017-07-01 |
| 2017-06-30 | -$21.61M | n/m | 2019-09-12, From 2016-07-01 |
| 2016-06-30 | -$18.52M | n/m | 2018-09-12, From 2015-07-01 |
| 2015-06-30 | -$20.61M | n/m | 2017-09-07, From 2014-07-01 |
| 2014-06-30 | -$19.12M | n/m | 2016-09-07, From 2013-07-01 |
| 2013-06-30 | -$16.89M | n/m | 2013-09-11, From 2012-07-01 |
| 2012-06-30 | -$3.27M | n/m | 2013-09-11, From 2011-07-01 |
| 2011-06-30 | -$5.75M | n/m | 2013-09-11, From 2010-07-01 |
| 2010-06-30 | -$5.41M | n/a | 2012-09-10, From 2009-07-01 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| Pluri Inc. (PLUR) | 2026-06-30 | -$19.59M | n/m |
| Prokidney Corp. (PROK) | 2025-12-31 | -$120.12M | n/m |
| ImageneBio, Inc. (IMA) | 2025-12-31 | -$47.84M | n/m |
| Inhibrx Biosciences, Inc. (INBX) | 2025-12-31 | -$129.79M | n/m |
| Scinai Immunotherapeutics Ltd. (SCNI) | 2025-12-31 | -$6.03M | n/m |
| Outlook Therapeutics, Inc. (OTLK) | 2025-09-30 | -$51.83M | n/m |
| Cardiff Oncology, Inc. (CRDF) | 2025-12-31 | -$37.92M | n/m |
| Humacyte, Inc. (HUMA) | 2025-12-31 | -$105.04M | n/m |
| Aligos Therapeutics, Inc. (ALGS) | 2025-12-31 | -$82.50M | n/m |
Compare PLUR, PROK, IMA, INBX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗